Mariana Segovia‐Mendoza

Efficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast cancer: preclinical and clinical evidence.

Mariana Segovia‐Mendoza, María Elena González-González, David Barrera et al. · PubMed · 2015 · 135 citations

Medicine, Oncology, Pharmacology +17

Calcitriol and its analogues enhance the antiproliferative activity of gefitinib in breast cancer cells

Mariana Segovia‐Mendoza, María Elena González-González, Isela Martínez-Reza et al. · The Journal of Steroid Biochemistry and Molecular Biology · 2014 · 62 citations

Medicine, Oncology, Pharmacology +13

Synergistic Antitumorigenic Activity of Calcitriol with Curcumin or Resveratrol is Mediated by Angiogenesis Inhibition in Triple Negative Breast Cancer Xenografts

Janice García‐Quiroz, Rocio Garcı́a-Becerra, Clara Santos‐Cuevas et al. · Cancers · 2019 · 60 citations · Full text

Medicine, Oncology, Pharmacology +12

The chemical environmental pollutants BPA and BPS induce alterations of the proteomic profile of different phenotypes of human breast cancer cells: A proposed interactome

Mariana Segovia‐Mendoza, Carmen T. Gómez de León, Rocio Garcı́a-Becerra et al. · Environmental Research · 2020 · 44 citations

Medicine, Oncology, Toxicology +16

Calcitriol Inhibits the Proliferation of Triple-Negative Breast Cancer Cells through a Mechanism Involving the Proinflammatory Cytokines IL-1<i>β</i>and TNF-<i>α</i>

Isela Martínez-Reza, David Barrera, Mariana Segovia‐Mendoza et al. · Journal of Immunology Research · 2019 · 43 citations · Full text

Medicine, Oncology, Pharmacology +17